Incretin-based therapies for diabetes such as dipeptidyl peptidase (DPP)-4 inhibitors or GLP-1 receptor agonists have also been experimentally shown to increase adiponectin synthesis and release both in vitro and in patients with T2D [198]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.